UY33159A - Compuestos y métodos para la modulación de quinasa e indicaciones de la misma - Google Patents
Compuestos y métodos para la modulación de quinasa e indicaciones de la mismaInfo
- Publication number
- UY33159A UY33159A UY33159A UY33159A UY33159A UY 33159 A UY33159 A UY 33159A UY 33159 A UY33159 A UY 33159A UY 33159 A UY33159 A UY 33159A UY 33159 A UY33159 A UY 33159A
- Authority
- UY
- Uruguay
- Prior art keywords
- kinase
- indications
- modulation
- compounds
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28993009P | 2009-12-23 | 2009-12-23 | |
| US38331810P | 2010-09-15 | 2010-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY33159A true UY33159A (es) | 2011-07-29 |
Family
ID=44196390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY33159A UY33159A (es) | 2009-12-23 | 2010-12-23 | Compuestos y métodos para la modulación de quinasa e indicaciones de la misma |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20110183988A1 (es) |
| EP (1) | EP2516438A4 (es) |
| JP (1) | JP5815558B2 (es) |
| KR (1) | KR20120112623A (es) |
| CN (1) | CN102753549A (es) |
| AR (1) | AR079690A1 (es) |
| AU (1) | AU2010336524B2 (es) |
| BR (1) | BR112012015745A2 (es) |
| CA (1) | CA2784393A1 (es) |
| MX (1) | MX2012007429A (es) |
| RU (1) | RU2012131373A (es) |
| TW (1) | TW201132639A (es) |
| UY (1) | UY33159A (es) |
| WO (1) | WO2011079133A2 (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| US20100190777A1 (en) | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CN105237530A (zh) | 2009-04-03 | 2016-01-13 | 豪夫迈罗氏公司 | 丙烷-1-磺酸{3-[5-(4-氯-苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟-苯基}-酰胺组合物及其用途 |
| WO2011057022A1 (en) | 2009-11-06 | 2011-05-12 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| RU2012125070A (ru) | 2009-11-18 | 2013-12-27 | Плексксикон, Инк. | Соединения и способы модулирования киназы и показания к их применению |
| RU2012131373A (ru) | 2009-12-23 | 2014-01-27 | Плексксикон, Инк. | Соединения и способы модулирования киназы, а также показания для такого модулирования |
| TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
| PT2672967T (pt) * | 2011-02-07 | 2018-12-07 | Plexxikon Inc | Compostos e métodos de modulação da quinase e suas indicações |
| WO2012135631A1 (en) | 2011-03-30 | 2012-10-04 | Arrien Pharmaeuticals Llc | Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors |
| WO2012138809A1 (en) * | 2011-04-05 | 2012-10-11 | Dawei Zhang | Heterocyclic compounds as kinase inhibitors |
| WO2012158957A2 (en) | 2011-05-17 | 2012-11-22 | Plexxikon Inc. | Kinase modulation and indications therefor |
| US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
| US9150570B2 (en) * | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| TWI601725B (zh) | 2012-08-27 | 2017-10-11 | 加拓科學公司 | 取代的氮雜吲哚化合物及其鹽、組合物和用途 |
| WO2014039714A2 (en) | 2012-09-06 | 2014-03-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2014100620A2 (en) | 2012-12-21 | 2014-06-26 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| RU2015131314A (ru) * | 2013-01-18 | 2017-02-27 | Ф. Хоффманн-Ля Рош Аг | 3-замещенные пиразолы и их применение в качестве ингибиторов dlk |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| MX2015012456A (es) | 2013-03-15 | 2016-02-03 | Plexxikon Inc | Compuestos heterociclicos y usos de los mismos. |
| BR112015026847A2 (pt) | 2013-04-22 | 2017-07-25 | Abbvie Inc | tiazóis e usos dos mesmos |
| CN105228983A (zh) | 2013-05-30 | 2016-01-06 | 普莱希科公司 | 用于激酶调节的化合物及其适应症 |
| WO2015134536A1 (en) | 2014-03-04 | 2015-09-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| JP6832846B2 (ja) | 2014-09-15 | 2021-02-24 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | ヘテロ環化合物およびその用途 |
| WO2016164641A1 (en) | 2015-04-08 | 2016-10-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CA2984899C (en) | 2015-05-06 | 2021-06-15 | Plexxikon Inc. | Synthesis of 1 h-pyrrolo[2,3-b]pyridin derivatives that modulate kinases |
| RU2730506C2 (ru) | 2015-05-06 | 2020-08-24 | Плексксикон Инк. | Твердые формы соединения, модулирующего киназы |
| CN107771178B (zh) | 2015-05-22 | 2021-04-06 | 普莱希科公司 | 杂环化合物的合成 |
| CN107801378A (zh) | 2015-05-22 | 2018-03-13 | 普莱希科公司 | 用于治疗braf‑v600相关的疾病的plx‑8394或plx‑7904 |
| US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| SG10201912386RA (en) | 2015-09-21 | 2020-02-27 | Plexxikon Inc | Heterocyclic compounds and uses thereof |
| US9938273B2 (en) | 2015-12-07 | 2018-04-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| JP6921846B6 (ja) | 2016-03-16 | 2021-09-15 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | キナーゼ調節およびその適応症のための化合物および方法 |
| TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症 |
| EP3558991A2 (en) | 2016-12-23 | 2019-10-30 | Plexxikon Inc. | Compounds and methods for cdk8 modulation and indications therefor |
| JP7300394B2 (ja) * | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
| JP2020511467A (ja) | 2017-03-20 | 2020-04-16 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | ブロモドメインを阻害する４−（１−（１，１−ジ（ピリジン−２−イル）エチル）−６−（３，５−ジメチルイソオキサゾール−４−イル）−１Ｈ−ピロロ［３，２−ｂ］ピリジン−３−イル）安息香酸の結晶形 |
| WO2018226846A1 (en) | 2017-06-07 | 2018-12-13 | Plexxikon Inc. | Compounds and methods for kinase modulation |
| KR102615829B1 (ko) | 2017-07-25 | 2023-12-20 | 플렉시콘 인코퍼레이티드 | 키나제를 조정하는 화합물의 제제 |
| EP3694855A1 (en) | 2017-10-13 | 2020-08-19 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
| CA3080197C (en) | 2017-10-27 | 2023-12-19 | Plexxikon Inc. | Formulations of a compound modulating kinases |
| US11858927B2 (en) * | 2018-01-31 | 2024-01-02 | Heparegenix Gmbh | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CN112119072A (zh) | 2018-03-20 | 2020-12-22 | 普莱希科公司 | 用于ido和tdo调节的化合物和方法，以及其适应症 |
| US11731968B2 (en) | 2018-06-21 | 2023-08-22 | Heparegenix Gmbh | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| US11912701B2 (en) | 2018-07-16 | 2024-02-27 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CA3136224A1 (en) | 2019-04-09 | 2020-10-15 | Plexxikon Inc. | Condensed azines for ep300 or cbp modulation and indications therefor |
| CN111217654A (zh) * | 2020-01-02 | 2020-06-02 | 陕西科技大学 | 钯催化的间位芳基化反应及其在维罗非尼类似物合成中的应用 |
| JP2023522949A (ja) | 2020-04-23 | 2023-06-01 | オプナ バイオ ソシエテ アノニム | Ｃｄ７３調節のための化合物及び方法並びにそれらの表示 |
| WO2022040512A1 (en) | 2020-08-21 | 2022-02-24 | Plexxikon Inc. | Combinational drug anticancer therapies |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040171062A1 (en) | 2002-02-28 | 2004-09-02 | Plexxikon, Inc. | Methods for the design of molecular scaffolds and ligands |
| CN102516417B (zh) * | 2002-09-06 | 2014-12-10 | 天蓝制药公司 | 用于传递治疗剂的以环糊精为基础的聚合物 |
| CA2503905A1 (en) | 2002-09-16 | 2004-03-25 | Plexxikon, Inc. | Crystal structure of pim-1 kinase |
| US20050048573A1 (en) | 2003-02-03 | 2005-03-03 | Plexxikon, Inc. | PDE5A crystal structure and uses |
| WO2004078923A2 (en) | 2003-02-28 | 2004-09-16 | Plexxikon, Inc. | Pyk2 crystal structure and uses |
| US20050079548A1 (en) | 2003-07-07 | 2005-04-14 | Plexxikon, Inc. | Ligand development using PDE4B crystal structures |
| NZ545326A (en) | 2003-07-17 | 2009-12-24 | Plexxikon Inc | PPAR active compounds |
| US7348338B2 (en) | 2003-07-17 | 2008-03-25 | Plexxikon, Inc. | PPAR active compounds |
| WO2005028624A2 (en) | 2003-09-15 | 2005-03-31 | Plexxikon, Inc. | Molecular scaffolds for kinase ligand development |
| EP1696920B8 (en) | 2003-12-19 | 2015-05-06 | Plexxikon Inc. | Compounds and methods for development of ret modulators |
| US20070066641A1 (en) | 2003-12-19 | 2007-03-22 | Prabha Ibrahim | Compounds and methods for development of RET modulators |
| US7517970B2 (en) | 2003-12-19 | 2009-04-14 | Plexxikon, Inc. | Nucleic acids encoding kinase and phosphatase enzymes, expression vectors and cells containing same |
| WO2006078287A2 (en) | 2004-05-06 | 2006-07-27 | Plexxikon, Inc. | Pde4b inhibitors and uses therefor |
| US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
| JP2008503473A (ja) | 2004-06-17 | 2008-02-07 | プレキシコン，インコーポレーテッド | Ｃ−ｋｉｔ活性を調節する化合物 |
| EP1786813A2 (en) | 2004-09-03 | 2007-05-23 | Plexxikon, Inc. | Bicyclic heteroaryl pde4b inhibitors |
| WO2006060535A2 (en) | 2004-11-30 | 2006-06-08 | Plexxikon, Inc. | Indole derivatives for use as ppar active compounds |
| JP2008521829A (ja) | 2004-11-30 | 2008-06-26 | プレキシコン，インコーポレーテッド | Ｐｐａｒ活性化合物 |
| US20060160135A1 (en) | 2004-12-08 | 2006-07-20 | Weiru Wang | SF-1 and LRH-1 modulator development |
| NZ563444A (en) | 2005-05-17 | 2011-04-29 | Plexxikon Inc | Pyrrolo(2,3-b)pyridine derivatives as protein kinase inhibitors |
| NZ565255A (en) | 2005-06-22 | 2010-04-30 | Plexxikon Inc | Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors |
| JP2009509932A (ja) | 2005-09-07 | 2009-03-12 | プレキシコン，インコーポレーテッド | Ｐｐａｒ活性化合物 |
| US20070072904A1 (en) | 2005-09-07 | 2007-03-29 | Jack Lin | PPAR active compounds |
| AU2006287521A1 (en) | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | PPARactive compounds |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| US7872018B2 (en) | 2006-12-21 | 2011-01-18 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| PE20090159A1 (es) | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
| MX2009009290A (es) | 2007-03-08 | 2009-09-10 | Plexxikon Inc | Compuestos activos en ppar. |
| US20100190777A1 (en) | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CA2639416C (en) * | 2007-09-11 | 2019-12-31 | F. Hoffmann-La Roche Ag | Diagnostic test for susceptibility to b-raf kinase inhibitors |
| PE20091846A1 (es) | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
| WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| US8110576B2 (en) | 2008-06-10 | 2012-02-07 | Plexxikon Inc. | Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications |
| CN102112478A (zh) | 2008-06-10 | 2011-06-29 | 普莱希科公司 | 用于激酶调节的5h-吡咯[2，3-b]吡嗪衍生物和其适应症 |
| TW201036973A (en) * | 2009-03-11 | 2010-10-16 | Plexxikon Inc | Compounds and uses thereof |
| US8129404B2 (en) | 2009-03-11 | 2012-03-06 | Plexxikon Inc. | Compounds and uses thereof |
| WO2010111527A1 (en) | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use |
| CN105237530A (zh) * | 2009-04-03 | 2016-01-13 | 豪夫迈罗氏公司 | 丙烷-1-磺酸{3-[5-(4-氯-苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟-苯基}-酰胺组合物及其用途 |
| WO2010129467A1 (en) | 2009-05-04 | 2010-11-11 | Plexxikon, Inc. | Compounds and methods for inhibition of renin, and indications therefor |
| TW201041888A (en) * | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| WO2011057022A1 (en) | 2009-11-06 | 2011-05-12 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| RU2012125070A (ru) | 2009-11-18 | 2013-12-27 | Плексксикон, Инк. | Соединения и способы модулирования киназы и показания к их применению |
| RU2012131373A (ru) | 2009-12-23 | 2014-01-27 | Плексксикон, Инк. | Соединения и способы модулирования киназы, а также показания для такого модулирования |
| TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
| US8642606B2 (en) | 2010-09-29 | 2014-02-04 | Plexxikon Inc. | ZAP-70 active compounds |
| PT2672967T (pt) | 2011-02-07 | 2018-12-07 | Plexxikon Inc | Compostos e métodos de modulação da quinase e suas indicações |
| TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
| WO2012158957A2 (en) | 2011-05-17 | 2012-11-22 | Plexxikon Inc. | Kinase modulation and indications therefor |
| US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| WO2014039714A2 (en) | 2012-09-06 | 2014-03-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2014100620A2 (en) | 2012-12-21 | 2014-06-26 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| MX2015012456A (es) | 2013-03-15 | 2016-02-03 | Plexxikon Inc | Compuestos heterociclicos y usos de los mismos. |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| CN105228983A (zh) | 2013-05-30 | 2016-01-06 | 普莱希科公司 | 用于激酶调节的化合物及其适应症 |
-
2010
- 2010-12-21 RU RU2012131373/04A patent/RU2012131373A/ru not_active Application Discontinuation
- 2010-12-21 WO PCT/US2010/061601 patent/WO2011079133A2/en active Application Filing
- 2010-12-21 CN CN2010800638309A patent/CN102753549A/zh active Pending
- 2010-12-21 US US12/975,239 patent/US20110183988A1/en not_active Abandoned
- 2010-12-21 JP JP2012546158A patent/JP5815558B2/ja not_active Expired - Fee Related
- 2010-12-21 BR BR112012015745A patent/BR112012015745A2/pt not_active IP Right Cessation
- 2010-12-21 MX MX2012007429A patent/MX2012007429A/es not_active Application Discontinuation
- 2010-12-21 EP EP10840075.5A patent/EP2516438A4/en not_active Withdrawn
- 2010-12-21 KR KR1020127019219A patent/KR20120112623A/ko not_active Application Discontinuation
- 2010-12-21 CA CA2784393A patent/CA2784393A1/en not_active Abandoned
- 2010-12-21 AU AU2010336524A patent/AU2010336524B2/en not_active Expired - Fee Related
- 2010-12-22 AR ARP100104871A patent/AR079690A1/es unknown
- 2010-12-22 TW TW099145373A patent/TW201132639A/zh unknown
- 2010-12-23 UY UY33159A patent/UY33159A/es not_active Application Discontinuation
-
2014
- 2014-10-14 US US14/514,232 patent/US9440969B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20150080372A1 (en) | 2015-03-19 |
| US20110183988A1 (en) | 2011-07-28 |
| CA2784393A1 (en) | 2011-06-30 |
| EP2516438A4 (en) | 2013-06-12 |
| WO2011079133A2 (en) | 2011-06-30 |
| CN102753549A (zh) | 2012-10-24 |
| US9440969B2 (en) | 2016-09-13 |
| EP2516438A2 (en) | 2012-10-31 |
| JP2013515736A (ja) | 2013-05-09 |
| AR079690A1 (es) | 2012-02-15 |
| RU2012131373A (ru) | 2014-01-27 |
| BR112012015745A2 (pt) | 2016-05-17 |
| TW201132639A (en) | 2011-10-01 |
| WO2011079133A3 (en) | 2011-11-17 |
| JP5815558B2 (ja) | 2015-11-17 |
| AU2010336524A1 (en) | 2012-07-05 |
| MX2012007429A (es) | 2012-07-23 |
| KR20120112623A (ko) | 2012-10-11 |
| AU2010336524B2 (en) | 2015-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY33159A (es) | Compuestos y métodos para la modulación de quinasa e indicaciones de la misma | |
| ES2685958T8 (es) | Procedimiento para la detección temprana de trenes | |
| UY33094A (es) | Procedimiento para la preparacion de dronedarona | |
| BR112012010640A2 (pt) | novos moduladores de quinase | |
| BR112014023162A2 (pt) | compostos e métodos para modulação quinase e indicações dos mesmos | |
| BRPI1011129A2 (pt) | métodos e compostos inibidores de janus cinase | |
| BRPI1010658A2 (pt) | métodos para integrar múltiplos domínios de gerenciamento | |
| CO6781493A2 (es) | Inhibidores de la faah | |
| BRPI1014572A2 (pt) | imidazoprazinas para uso como inibidores de cinase | |
| DK2151833T3 (da) | Transformersystem | |
| BRPI0915231A2 (pt) | compostos inibidores de quinase e métodos de uso | |
| BR112012017441A2 (pt) | compostos e métodos | |
| ES2529767T4 (es) | Procedimiento y aparato para la utilización de precodificación factorizada | |
| BR112013014943A2 (pt) | compostos úteis para o tratamento de aids | |
| DK2529050T3 (da) | Jernbane- eller metroskinnestøtte | |
| BRPI1015367A2 (pt) | imidazotiodiazois para uso como inibidores de cinase | |
| BRPI0923401A2 (pt) | Métodos para o preparo de aril amidas. | |
| FR2936703B1 (fr) | Disque intervertebral | |
| DK2462108T3 (da) | Fremgangsmåde til fremstilling af pyrazolcarboxylsyreamider | |
| DK2655360T3 (da) | Fremgangsmåde til fremstilling af n-sulfonylsubstituerede oxindoler | |
| IT1401837B1 (it) | Protesi discale intervertebrale | |
| ITMI20080888A1 (it) | Procedimento per la preparazione di zileuton | |
| ES1073254Y (es) | Electrovalvula para la regulacion de fluidos | |
| ES1073150Y (es) | Utensilio-soporte para instrumentos de cocina | |
| ES1074944Y (es) | Envase monodosis para dentifricos y similares |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20190228 |